For IPO Boutique's "scale of 1 to 5" BUY rating on Zafgen, Inc., and our comprehensive analysis, click "Buy Market Research".
About Zafgen, Inc. (adapted from Zafgen, Inc. prospectus): They are a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for patients affected by complex metabolic diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "ZFGN" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
Used our Comprehensive Single Promo Advisory and want more?